TrialsgrambetaRCTs are beautiful

EV-302 / KEYNOTE-A39

2024

Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Carcinoma

In 886 patients with untreated advanced urothelial carcinoma, enfortumab vedotin + pembrolizumab improved progression-free and overall survival compared with platinum-based chemotherapy.

Result

Efficacy: PFS and OS (co-primary)HR 0.47

Below 1 favours enfortumab vedotin + pembrolizumab, above 1 favours platinum-based chemotherapy.

Event rates Enfortumab vedotin + pembrolizumab 31.5 vs platinum-based chemotherapy 16.1 months

Also reported: PFS HR 0.45; ORR 67.7% vs 44.4%.

Original publication
Subtopic
Urothelial 1L
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Powles T, et al. N Engl J Med. 2024;390(10):875-888.doi 10.1056/NEJMoa2312117

Discussion & critique

Displaced platinum-based chemotherapy as first-line standard in advanced urothelial cancer: the largest OS gain ever shown in this setting.